Cardiovascular effects of the DPP-4 inhibitors (Q37984287)

26 August 2017

Cardiovascular effects of the DPP-4 inhibitors (English)

1 reference

26 August 2017

1 reference

Tessey Jose

1

1 reference

PubMed ID

22337893

26 August 2017

Silvio E Inzucchi

series ordinal

2

1 reference

PubMed ID

22337893

26 August 2017

language of work or name

English

0 references

publication date

15 February 2012

1 reference

Diabetes and Vascular Disease Research

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

109-116

1 reference

26 August 2017

2

1 reference

Standards of medical care in diabetes--2011.

26 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

Adipocyte turnover: relevance to human adipose tissue morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111436236

21 January 2018

Identifiers

DOI

10.1177/1479164111436236

1 reference

26 August 2017

1 reference

PubMed ID

22337893